Consultant Medical Oncologist
(MBBS BSc FRCP PhD FMedSci)
Director of the Gestational Trophoblastic Disease and Malignant Ovarian Germ Cell Tumour Centres.
Head of Supra-regional Assay Laboratory for Tumour Markers.
Joined in 2011.
Michael Seckl trained in medicine at UCL/UCLH gaining a BSc in immunology in 1983 and his MBBS in 1986. He then obtained his MRCP before entering specialist training in Medical Oncology between 1989-1995.
During this period he spent 3 years at the Imperial Cancer Research Fund (London Research Institute; LRI) working on signal transduction in model and lung cancer cells and was awarded his PhD in 1995 (University of London). He was then appointed as a Senior Lecturer at Imperial College whilst working as a post-doctoral fellow at the LRI enabling a series of successful grant applications to support his ongoing work on drug resistance and metastasis mechanisms in cancer. His clinical appointment also linked him to the national trophoblastic disease service and so, a second stream of research was established.
He is an international leader in trophoblastic disease, past-president and current treasurer of the international trophoblastic disease society (ISSTD.org), president of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD.com), is a visiting Professor at Peking Union Medical College and serves on several editorial boards and grants committees. He leads the gynae theme of the European Rare Adult Cancer (EURACAN) network which aims to improve the care of women with these rare tumours across Europe.
He has chaired/organised many national and international meetings related to trophoblastic disease, lung cancer and cell signalling. He is chair of the London Lung Cancer Alliance. His work is supported by CR-UK, MRC, EU-FP7, AICR, Dept of Health, industry and several other charities. This has resulted in over 240 peer-reviewed publications many appearing in leading clinical and scientific journals. In 2017 he was awarded a Fellowship of the Academy of Medical Sciences (FMedSci).